Clinical Trial

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

Study acronym: BDHCLL001
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2019 (before its estimated December 15, 2022 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.
Trial Details
NCT Number NCT03980002
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Chronic Lymphocytic Leukemia
Enrollment 50 participants
Start Date 2019-05-15
Primary Completion 2022-12-15 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2019-06-10